| III-02 Linda Aulin Tapping into the potential of pharmacometrics in preclinical infection models: a low-hanging fruit or joined efforts needed? Thursday 10:15-11:45 |
| III-03 Emily Behrens Influence of interoccasion variability on parameter estimates of a population pharmacokinetic model under various sparse study designs Thursday 10:15-11:45 |
| III-09 Lucia Diaz Garcia Individualized tacrolimus dosing in pediatric kidney transplantation: development of PBPK-based predictive models, simulations and applications (ModSimTer-Tacro Study) Thursday 10:15-11:45 |
| III-17 Daniel Kaschek How to reduce the total number of samples in a bioequivalence study without impacting statistical power Thursday 10:15-11:45 |
| III-20 Lina Keutzer Model-based experimental design recommendations for in vivo studies of the novel anti-tuberculosis drug MPL-447 improve characterization of PK and PD Thursday 10:15-11:45 |
| III-33 Romain Leroux Design evaluation and optimisation in nonlinear mixed effects models with the R package PFIM 6.0 Thursday 10:15-11:45 |
| III-44 Claude Magnard Pharmacokinetic Modeling of Fentanyl Citrate and Norfentanyl in Calves Using a Nonlinear Mixed-Effects Approach Thursday 10:15-11:45 |
| III-47 Frederico Martins Establishment of Virtual Bioequivalence via DoE-PBPM Model: A Donepezil Case Study Thursday 10:15-11:45 |
| III-55 Ana Novakovic Empirical Power Evaluations of an Item Response Model in Parkinson’s Disease Patients Thursday 10:15-11:45 |
| III-80 Hanna Silber Baumann Dose confirmation based on population pharmacokinetics within LUMINESCE (NCT04963270); a Phase III, randomized, double-blind, placebo-controlled study evaluating satralizumab in patients with generalized myasthenia gravis Thursday 10:15-11:45 |
| III-96 Yuanxi Zou Evaluating two strategies for the design of pediatric pharmacokinetic studies Thursday 10:15-11:45 |
